Medical device firm Angiotech of Vancouver, British Columbia, has received clearance from the U.S. Food and Drug Administration for its 5-fluorouracil-coated (5-FU) central venous catheter, the company reported.
The device is the company's first drug-eluting product researched and developed completely in-house, according to Angiotech. 5-FU helps prevent catheter-related infections as compared to catheters coated with chlorhexidine/silver sulfadiazine (CH-SS), the company said.
Related Reading
Cook, Angiotech restructure licensing deal, September 24, 2004
Copyright © 2008 AuntMinnie.com